AIM ImmunoTech (AIM) Common Equity (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Common Equity came in at $2.1 million in Q1 2026, up 154.45% YoY from $825321.0 in Q1 2025, and up 121.47% on a QoQ basis from -$9.8 million in Q4 2025.
AIM ImmunoTech (AIM) Common Equity (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Common Equity data on file, last reported at $2.1 million in Q1 2026.
- Quarterly Common Equity rose 154.45% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 154.45% YoY) and the FY2025 annual result came in at -$9.8 million, down 640.02% from the prior year.
- Common Equity climbed to $2.1 million in Q1 2026, from -$9.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $53.3 million in Q1 2022 to a low of -$9.8 million in Q4 2025.
- A 5-year average of $15.9 million and a median of $6.1 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity plunged 640.02% — and 2026, when it jumped 154.45%.
- Tracing AIM's Common Equity over 5 years: stood at $38.5 million in 2022, then slumped by 73.4% to $10.2 million in 2023, then plunged by 112.92% to -$1.3 million in 2024, then sank by 640.02% to -$9.8 million in 2025, then soared by 121.47% to $2.1 million in 2026.
- The last three Common Equity figures came in at $2.1 million (Q1 2026), -$9.8 million (Q4 2025), and -$6.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.19 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.58 Bn | 77.59 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.52 Bn | 51.38 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.67 Bn | 27.36 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.27 Bn | 26.11 Bn | 358.27 Mn | 757.49 Mn |
| 8 | BioNTech SE | 27.14 Bn | 8.75 Bn | 668.28 Mn | 22.38 Bn |
| 9 | Royalty Pharma | 27.12 Bn | 26.28 Bn | - | 9.79 Bn |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | 7.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.74 Mn |
| Mar 31, 2026 | 2.10 Mn |
| Dec 31, 2025 | -9.78 Mn |
| Sep 30, 2025 | -6.08 Mn |
| Jun 30, 2025 | -6.55 Mn |
| Mar 31, 2025 | -3.86 Mn |
| Dec 31, 2024 | -1.32 Mn |
| Sep 30, 2024 | 2.91 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Mar 31, 2024 | 4.83 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Sep 30, 2023 | 22.60 Mn |
| Jun 30, 2023 | 30.14 Mn |
| Mar 31, 2023 | 34.99 Mn |
| Dec 31, 2022 | 38.47 Mn |
| Sep 30, 2022 | 42.70 Mn |
| Jun 30, 2022 | 48.78 Mn |
| Mar 31, 2022 | 53.30 Mn |
| Dec 31, 2021 | 56.88 Mn |
| Sep 30, 2021 | 62.05 Mn |